In renal failure-related anemia, which erythropoiesis-stimulating agent can be used as a longer-acting alternative to epoetin alfa?

In renal failure-related anemia, which erythropoiesis-stimulating agent can be used as a longer-acting alternative to epoetin alfa?

• A. Epoetin alfa
• B. Darbepoetin alfa
• C. Filgrastim
• D. Iron sucrose

Answer: (B)

In renal failure-related anemia, stimulating red blood cell production is key because the kidneys aren’t making enough erythropoietin. Darbepoetin alfa is a longer-acting erythropoiesis-stimulating agent because it has extra carbohydrate chains and increased sialylation, which lengthens its circulating half-life. This pharmacokinetic change allows effective RBC production with less frequent dosing (often weekly or every other week) compared with epoetin alfa, which usually requires more frequent administration. The goal is to maintain hemoglobin levels while reducing injection frequency. It’s also important to remember that ESAs work best when iron stores are adequate, and responses can be limited if iron or other factors are deficient. Filgrastim is a granulocyte-stimulating factor for neutrophils, not red cells, and iron sucrose provides iron rather than stimulating erythropoiesis, so they don’t serve as the longer-acting alternative to epoetin alfa.

In renal failure-related anemia, stimulating red blood cell production is key because the kidneys aren’t making enough erythropoietin. Darbepoetin alfa is a longer-acting erythropoiesis-stimulating agent because it has extra carbohydrate chains and increased sialylation, which lengthens its circulating half-life. This pharmacokinetic change allows effective RBC production with less frequent dosing (often weekly or every other week) compared with epoetin alfa, which usually requires more frequent administration. The goal is to maintain hemoglobin levels while reducing injection frequency. It’s also important to remember that ESAs work best when iron stores are adequate, and responses can be limited if iron or other factors are deficient. Filgrastim is a granulocyte-stimulating factor for neutrophils, not red cells, and iron sucrose provides iron rather than stimulating erythropoiesis, so they don’t serve as the longer-acting alternative to epoetin alfa.